Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Shares of Amarin Corp (NASDAQ:AMRN) rose 2.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 100.00% over the past year to ($0.00), which beat the estimate of ($0.05).

Amarin: Q1 Earnings Insights

Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiatives. A search is underway at Amarin for a new general counsel. Mr. Kennedy has agreed to continue in his role until a replacement is hired and manage certain legacy matters through the end of 2021. He is committed to a smooth transition of responsibilities.

Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel

VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, 3

Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2

DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2021 financial results and provide an operational update on Thursday, April 29, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021

Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021

Amarin received approval to market their drug Vascepa in Europe, but the market shrugged off the news and sent shares lower. As the company struggles with sales and legal battles, a new CEO has been hired.

With Their European Approval In Hand, Amarin Signals A Strategic Shift With A New CEO

The stock price of Amarin Corporation plc (Nasdaq: AMRN) fell by over 4% pre-market. This is why it happened.

AMRN Stock: Over 4% Decrease Pre-Market Explanation

John Thero to Retire as President and CEO on August 1, 2021

Amarin Announces CEO Succession Plan

Nano-X Imaging

Invitae

All three companies have enjoyed major growth catalysts since the start of 2021.

3 Top Healthcare Stocks to Buy in April

This biotech's heart medication could be wildly lucrative.

Should You Buy Amarin in April?

Reimbursement dossiers for first 10 countries to be filed in coming months

Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication

Intuitive Surgical

Amarin and Accelerate Diagnostics are healthcare companies with significant upside.

2 Great Stocks Under $10 per Share

The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The approval covers reducing the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor.

Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl

The stock price of Amarin Corporation plc (NASDAQ: AMRN) increased by over 5% pre-market. This is why it happened.

AMRN Stock Price Increased Over 5% Pre-Market: Why It Happened

Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in REDUCE-IT® 1, 2

Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk

HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included icosapent ethyl (Vascepa) in 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults, published in the Canadian Journal of Cardiology. HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corporation Plc (NASDAQ: AMRN).

Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases

Arcos Dorados Hlds

Colony Northstar Credit Real Estate, Inc. Class A

CoreCivic

DHT Holdings

Centrais Eletricas Brasileiras

Frontline

Itau Unibanco Holding S.A.

Cia de Saneamento Basico do Estado de Sao Paulo

Sirius XM Holdings Inc

There are plenty of cheap stocks out there, but don't confuse inexpensive for undervalued; these 10 stocks under $10 should be avoided. The post 10 Cheap Stocks Under $10 That Don't Deserve Your Time or Money appeared first on InvestorPlace.

10 Cheap Stocks Under $10 That Don't Deserve Your Time or Money

Amarin Corporation plc (NASDAQ: AMRN) has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Conference 2021.

Amarin's Vascepa Associated With Stroke Reduction

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

Cowen

Amarin Corporation plc (AMRN) CEO John Thero Presents at Cowen 41st Annual Health Care Conference (Transcript)

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin Corporation plc's (AMRN) CEO John Thero on Q4 2020 Results - Earnings Call Transcript

The drugmaker topped analysts' top- and bottom-line expectations despite challenges from a generic rival and the pandemic.

News for Amarin Corporation Plc Stock (AMRN)